News Breaks |
|
|
| January 15, 2013 |
| 08:26 EDT |  | ALKS | Alkermes price target raised to $30 from $27 at Citigroup
Citigroup says there is substantial further value to be recognized in shares of Alkermes following the 20% rise over the past few months given the company's wholly-owned late-stage assets, such as ALKS-9070 for schizophrenia. The firm raised its price target for shares to $30 from $27 and keeps a Buy rating on the stock. |
|
|
News For ALKS From The Last 14 Days Check below for free stories on ALKS the last two weeks. |
|
|
| There are no results for ALKS |
|
|
|
|
